{
"endpoint": "clinicaltrials",
"count": 1,
"truncated": true,
"took_ms": 3178,
"items": [
{
"recordType": "study",
"nctId": "NCT02654665",
"title": "Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults",
"officialTitle": "Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults",
"acronym": "CGH-LiNASH",
"status": "UNKNOWN",
"lastKnownStatus": "RECRUITING",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE3"
],
"conditions": [
"Non-alcoholic Fatty Liver Disease (NAFLD)",
"Weight Loss",
"Non-alcoholic Steatohepatitis (NASH)"
],
"interventions": [
"Lifestyle modification",
"Liraglutide"
],
"interventionTypes": [
"BEHAVIORAL",
"DRUG"
],
"leadSponsor": "Changi General Hospital",
"sponsorClass": "OTHER",
"enrollmentCount": 36,
"enrollmentType": "ESTIMATED",
"startDate": "2014-03",
"primaryCompletionDate": "2017-12",
"completionDate": "2018-12",
"firstPosted": "2016-01-13",
"lastUpdatePosted": "2018-01-30",
"sex": "ALL",
"minimumAge": "21 Years",
"maximumAge": "65 Years",
"healthyVolunteers": true,
"locationCount": 1,
"countries": [
"Singapore"
],
"locations": [
"Changi General Hospital, Singapore, Singapore"
],
"primaryOutcomeMeasures": [
"Improvement in NASH"
],
"briefSummary": "Non-alcoholic fatty liver disease (NAFLD) is defined by presence of hepatic steatosis (fat accumulation in liver cells), either by imaging or by biopsy and absence of causes for secondary hepatic fat accumulation such as significant alcohol consumption, medications, or hereditary disorders. In the majority of patients, NAFLD is associated with risk factors for cardiovascular disease such as obesity, diabetes mellitus, and high cholesterol, and may lead to irreversible liver damage. Non-alcoholic steatohepatitis (NASH) is a more severe form of NAFLD and is present in up to 30% of obese adults. NASH is defined by hepatic steatosis and inflammation with hepatocyte injury with or without fibrosis (hardening of the liver).\n\nThe prevalence, morbidity and mortality of NAFLD is increasing, particularly in the Asia-Pacific region where there will be an estimated 300 million obese people by 2030. Weight loss is the first-line treatment for NAFLD in obese individuals, but the utility of lifestyle modification with diet and exercise is limited by difficulties in sustaining compliance and by eventual weight regain. Bariatric (weight loss) surgery produces the greatest amount of weight loss but is limited by cost, patient acceptance, and complications. The efficacy of drugs for NASH, such as vitamin E and medication to lower cholesterol and glucose, remains unclear. Liraglutide, a glucagon-like peptide (GLP-1) analogue, is an injectable medication which has been shown to induce weight loss and lower glucose in obese adults. There is little information on the effects of GLP-1 analogues on NASH, particularly in comparison to other modalities of weight loss such as surgery. This study aims to compare the efficacy and safety of lifestyle modification, liraglutide and surgery, for weight loss in conjunction with reducing severity of NASH, and for insulin resistance, high cholesterol and other cardiovascular risk factors.",
"eligibilityCriteria": "Inclusion Criteria:\n\n* Body mass index \\> 27.5 kg/m2\n* Waist circumference (WC) \\> 90 cm (male) or \\> 80 cm (female)\n* Diagnosis of NASH based on Liver Function Test Results ,Ultrasound Hepato-Biliary System (HBS) findings and / or Liver Biopsy\n* HbA1c \\< 8%\\* \\*Subjects in the bariatric surgery arm will not need to fulfil this criterion.\n\nExclusion Criteria:\n\n* Currently using insulin-sensitising agents (metformin, pioglitazone), weight loss medication (orlistat, phentermine). Patients taking any of these drugs will require a three month washout period before enrolment.\n* Pregnancy\n* Significant cardiovascular or respiratory disease\n* Renal impairment with eGFR \\< 60 ml/min\n* Hepatitis B or C carrier, liver disease other than NAFLD\n* History of pancreatitis\n* Personal or family history of multiple endocrine neoplasia type 2 or thyroid carcinoma\n* Untreated hypothyroidism or hyperthyroidism\n* Current psychiatric illness\n* Cardiac pacemaker, metallic prosthetic heart valves and other contraindications to MRI scan\n* Current smoker\n* Alcohol intake ≥ 14 units/week",
"url": "https://clinicaltrials.gov/study/NCT02654665",
"scrapedAt": "2026-11-11T16:07:29.999Z"
}
]
}
curl --location --request GET 'https://zylalabs.com/api/14932/clinical+trial+studies+api/39019/search+clinical+trial+studies?query=diabetes&limit=2' --header 'Authorization: Bearer YOUR_API_KEY'
After signing up, every developer is assigned a personal API access key, a unique combination of letters and digits provided to access to our API endpoint. To authenticate with the Clinical Trial Studies API simply include your bearer token in the Authorization header.
| Header | Description |
|---|---|
Authorization
|
Required
Should be Bearer access_key. See "Your API Access Key" above when you are subscribed.
|
No long-term commitment. Upgrade, downgrade, or cancel anytime.
(Save 2 months with annual billing 🎉)
Registered clinical studies with NCT id, title, status, phase, sponsor, conditions and dates.
Every response is JSON with a count, a took_ms field and an items array of flat records ready to store or query.
No. Requests are handled server-side; you only send your API key and the parameters described in this endpoint.
Each call reads the source live, so the records reflect the state of the upstream source at request time.
You receive an explicit error status instead of an empty result, so a failure is never mistaken for no data.
Yes, each endpoint caps the number of records per request; the maximum is stated in the limit parameter.
To obtain your API key, first sign in to your account and navigate to the API you want to use. From the API's Pricing section, choose a plan and complete the subscription process. Once subscribed, return to the API page and you will see your API Access Key displayed at the top of the documentation page. You can use this key to authenticate your requests.
You can’t switch APIs during the free trial. If you subscribe to a different API, your trial will end and the new subscription will start as a paid plan.
The free trial lasts for 7 days and allows you to make up to 50 API requests.
No, the free trial is available only once, so we recommend using it on the API that interests you the most. Most of our APIs offer a free trial, but some may not include this option.
Yes. If the API offers a free trial, you will see a "Free 7-Day Trial" option in its Pricing section. The trial lasts for 7 days and allows up to 50 API requests, enabling you to evaluate the API before subscribing to a paid plan.
Zyla API Hub is like a big store for APIs, where you can find thousands of them all in one place. We also offer dedicated support and real-time monitoring of all APIs. Once you sign up, you can pick and choose which APIs you want to use. Just remember, each API needs its own subscription. But if you subscribe to multiple ones, you'll use the same key for all of them, making things easier for you.
You can monitor your API usage through the response headers included with every request:
x-zyla-api-calls-monthly-used: Shows the total number of API requests you have used during the current billing period.
x-zyla-api-calls-monthly-remaining: Shows the number of API requests you have remaining for the current billing period.
Yes, you can cancel your subscription at any time. Simply go to the Pricing section of the API you're subscribed to and click the "Unsubscribe" button.
Please note that upgrades, downgrades, and cancellations take effect immediately. Once your subscription is canceled, access to the service will end immediately, regardless of any remaining API calls in your quota.
Please have a look at our Refund Policy: https://zylalabs.com/terms#refund